Propranolol can help reduce some symptoms of benzodiazepine withdrawal, but the evidence is mixed and it is not a standalone solution. In clinical studies, 27 to 80 percent of patients still experienced withdrawal symptoms while taking propranolol, depending on the study. It works best as an add-on to a gradual tapering plan rather than a replacement for one.
What Propranolol Actually Does During Withdrawal
Propranolol is a beta-blocker, meaning it blocks the effects of adrenaline and related stress hormones on your heart, blood vessels, and muscles. During benzodiazepine withdrawal, your nervous system goes into overdrive. Your heart races, your hands shake, you sweat, and you feel a surge of physical anxiety. Propranolol dials down these specific responses by preventing adrenaline from reaching its targets.
The physical symptoms it targets include rapid heartbeat, palpitations, tremor, elevated blood pressure, and rapid breathing. These are some of the most distressing parts of withdrawal for many people, and blocking them can make the process more tolerable.
Does It Help With Anxiety, or Just Physical Symptoms?
This is where the research gets interesting. You might assume a drug that calms physical symptoms would only help with the body side of withdrawal, not the mental side. But one placebo-controlled crossover study found the opposite: when propranolol was added to diazepam treatment, it significantly improved psychological symptoms of anxiety. Surprisingly, it was less effective for somatic (body-based) symptoms in that particular study.
The likely explanation is that physical and psychological anxiety feed each other. When your heart stops pounding and your hands stop shaking, your brain interprets the situation as less threatening. This feedback loop means that even though propranolol works primarily on the body, the calming effect can ripple into how you feel mentally. That said, propranolol does not act directly on the brain’s anxiety circuits the way benzodiazepines do, so it won’t eliminate the psychological dimensions of withdrawal on its own.
What the Clinical Evidence Shows
The most frequently cited study on this topic followed 23 patients being treated for benzodiazepine dependence with propranolol. Of those, 8 patients (about 35 percent) stopped their benzodiazepines entirely, and another 11 achieved at least a 50 percent reduction in their original dose. The researchers described the outcome as “moderately successful” and concluded that propranolol was helpful in reducing withdrawal symptoms.
Other studies have been less encouraging. In one trial where patients stopped benzodiazepines abruptly and took propranolol instead, 27 to 45 percent still experienced withdrawal symptoms. A separate study of severely dependent patients found that roughly 80 percent experienced withdrawal symptoms despite propranolol, which was no better than standard approaches. A broader review of adjunctive treatments for benzodiazepine discontinuation concluded that strategies using propranolol, clonidine, and carbamazepine have been “inconsistently effective.”
The takeaway from the research overall: propranolol can take the edge off, but it cannot reliably prevent withdrawal symptoms, especially in people with severe or long-standing dependence.
An Important Limitation: No Seizure Protection
One of the most dangerous risks of benzodiazepine withdrawal is seizures, particularly with abrupt discontinuation or rapid tapers. Propranolol does not lower your seizure threshold or provide any anticonvulsant protection. This is a critical distinction. While it may make you feel better by calming your heart rate and tremor, it does nothing to address the underlying neurological instability that can lead to seizures. Masking physical symptoms with propranolol while skipping a proper taper could create a false sense of security.
How It Compares to Other Adjunct Options
Propranolol is one of several medications that have been tried alongside benzodiazepine tapering. Clonidine, which works on a different part of the stress response system (alpha receptors rather than beta receptors), is another common option. Clonidine tends to lower blood pressure and reduce the overall “fight or flight” activation, while propranolol more specifically targets heart rate and tremor. Neither has shown consistently strong results for benzodiazepine withdrawal in clinical trials.
Anticonvulsants like carbamazepine have also been studied as adjuncts, with the added potential benefit of seizure protection that propranolol lacks. No single adjunct medication has emerged as a clear winner. The most reliable approach remains a gradual taper of the benzodiazepine itself, typically reducing the dose by 10 to 25 percent every one to two weeks, with the entire process usually taking four to eight weeks.
Who Should Avoid Propranolol
Propranolol is not safe for everyone. It should not be used by people with asthma or a history of bronchospasm, because it can constrict the airways. People with a very slow heart rate, certain types of heart block, decompensated heart failure, or extremely low blood pressure are also not candidates. If you have diabetes or thyroid problems, propranolol can mask warning signs of low blood sugar or hide symptoms of an overactive thyroid, making those conditions harder to monitor.
Where Propranolol Fits in a Withdrawal Plan
Propranolol is best understood as a comfort medication, not a treatment for benzodiazepine dependence itself. It can make the physical experience of withdrawal less intense for some people, particularly those whose most distressing symptoms are a racing heart, visible tremor, or the physical sensations of panic. It works best when paired with a structured, gradual taper rather than used as a justification for stopping benzodiazepines abruptly.
If your prescriber suggests propranolol during a taper, it is a reasonable option for symptom relief. If someone suggests using it instead of a taper, that is a different situation entirely, and one where the evidence does not support skipping the slow dose reduction that protects against seizures and rebound symptoms.